Linked Life Data

11584358

Source:http://linkedlifedata.com/resource/pubmed/id/11584358

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4 Pt 1
pubmed:dateCreated
2001-10-3
pubmed:abstractText
It is well known that chronic inflammatory conditions involving the bile ducts predispose to the development of bile duct carcinoma, although the relationship between chronic inflammation and malignant transformation is unclear. In this study, by combining immunohistochemistry and computer imaging techniques, we quantified and compared the cyclooxygenase-2 (COX-2) protein expression levels of epithelial cells according with their histopathological backgrounds. This technique revealed that the highest levels of COX-2 were expressed in bile duct carcinoma cells, mainly in cytoplasm, and the expression pattern was homogenous and abundant. Moderate levels of COX-2 protein expression were also observed in noncancerous epithelial cells with inflammatory reaction, but the staining intensity was heterogeneous among the positive cells exhibiting inflammation. In contrast, only scattered weak reactivity of COX-2 protein was observed in the noncancerous bile duct epithelial cells without inflammatory reaction. Moreover, bile duct epithelial cells in primary sclerosing cholangitis (PSC) showed very strong expression of COX-2 protein, that was comparable with carcinoma cells. On the other hand, primary biliary cirrhosis (PBC) epithelial cells showed moderate levels of COX-2 expression. In addition, specific COX-2 inhibitors, JTE-522 and NS-398, directly inhibited the growth of 4 bile duct carcinoma and 1 gall bladder carcinoma cell lines that expressed COX-2 protein, in vitro. These data suggest that COX-2 expression might regulate carcinogenesis of bile duct epithelial cells in inflammatory regions and tumor progression in this cancer. The data also suggest that COX-2 selective inhibitors might have therapeutic effects not only on bile duct carcinoma, but other hepatobiliary carcinomas.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0270-9139
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
638-50
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11584358-Animals, pubmed-meshheading:11584358-Bile Duct Neoplasms, pubmed-meshheading:11584358-Bile Ducts, pubmed-meshheading:11584358-Cell Division, pubmed-meshheading:11584358-Cholangitis, Sclerosing, pubmed-meshheading:11584358-Colonic Neoplasms, pubmed-meshheading:11584358-Cyclooxygenase 2, pubmed-meshheading:11584358-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:11584358-Cyclooxygenase Inhibitors, pubmed-meshheading:11584358-Epithelial Cells, pubmed-meshheading:11584358-Hepatocytes, pubmed-meshheading:11584358-Humans, pubmed-meshheading:11584358-Immunohistochemistry, pubmed-meshheading:11584358-Isoenzymes, pubmed-meshheading:11584358-Liver Cirrhosis, Biliary, pubmed-meshheading:11584358-Membrane Proteins, pubmed-meshheading:11584358-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:11584358-RNA, Messenger, pubmed-meshheading:11584358-Rabbits, pubmed-meshheading:11584358-Tumor Cells, Cultured
pubmed:year
2001
pubmed:articleTitle
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
pubmed:affiliation
Department of Surgery and Clinical Oncology Graduate School of Medicine, Osaka University, Osaka, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't